A 2024 safety review in ScienceDirect noted that tirzepatide may have slightly better GI tolerability than semaglutide, likely because of its dual mechanism ( ScienceDirect , 2024)
FDA-Approved Indications at a Glance Table 3
Tolerance (i.e., need for increased amounts or diminished effect with continued use of the same amount)* Experiencing withdrawal (opioid withdrawal syndrome) or taking opioids (or a closely related substance) to relieve or avoid withdrawal symptoms.* *Patients who are taking opioids as prescribed by a healthcare provider may experience tolerance and withdrawal, but in that case, do not have opioid use disorder
Novo Nordisk has said that more than 200,000 Wegovy prescriptions are filled in the US each week
Lack of Clinical Evidence Critical gaps in knowledge: Zero randomized controlled trials on microdosing GLP-1 agonists No long-term safety data for alternative dosing regimens Unknown effects on cardiovascular outcomes Potential for reduced efficacy not captured in models 2
grilling over medium heat